presentation.mkdn 15 KB

123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463
  1. ---
  2. title: Bioinformatic analysis of complex, high-throughput genomic and epigenomic data in the context of $\mathsf{CD4}^{+}$ T-cell differentiation and diagnosis and treatment of transplant rejection
  3. author: |
  4. Ryan C. Thompson \
  5. Su Lab \
  6. The Scripps Research Institute
  7. date: October 24, 2019
  8. theme: Boadilla
  9. aspectratio: 169
  10. fontsize: 14pt
  11. ---
  12. ## Organ transplants are a life-saving treatment
  13. ::: incremental
  14. * 36,528 transplants performed in the USA in 2018[^organdonor]
  15. * 100 transplants every day!
  16. * Over 113,000 people on the national transplant waiting list as of
  17. July 2019
  18. :::
  19. [^organdonor]: [organdonor.gov](https://www.organdonor.gov/statistics-stories/statistics.html)
  20. ## Organ donation statistics for the USA in 2018[^organdonor]
  21. \centering
  22. ![](graphics/presentation/transplants-organ-CROP.pdf)
  23. ## Types of grafts
  24. A graft is categorized based on the relationship between donor and recipient:
  25. . . .
  26. ::: incremental
  27. * **Autograft:** Donor and recipient are the *same individual*
  28. * **Allograft:** Donor and recipient are *different individuals* of
  29. the *same species*
  30. * **Xenograft:** Donor and recipient are *different species*
  31. :::
  32. ## Recipient T-cells reject allogenic MHCs
  33. :::::::::: {.columns}
  34. ::: {.column width="55%"}
  35. :::: incremental
  36. <!-- Vertical alignment hacks -->
  37. \rule{\linewidth}{0pt}
  38. \vspace*{12pt}
  39. * TCR binds to both antigen *and* MHC surface \vspace{10pt}
  40. * HLA genes encoding MHC proteins are highly polymorphic \vspace{10pt}
  41. * Variants in donor MHC can trigger the same T-cell response as a
  42. foreign antigen
  43. \vspace*{12pt}
  44. \rule{\linewidth}{0pt}
  45. ::::
  46. :::
  47. ::: {.column width="40%"}
  48. <!-- ![\footnotesize Janeway's Immunobio- logy (2012), Fig. 9.19](graphics/presentation/janeway-fig9.19-TCR.png){ height=70% } -->
  49. ![TCR binding to self (right) and allogenic (left) MHC\footnotemark](graphics/presentation/tcr_mhc.jpg){ height=70% }
  50. :::
  51. ::::::::::
  52. \footnotetext[3]{\href{https://doi.org/10.1016/j.cell.2007.01.048}{Colf, Bankovich, et al. "How a Single T Cell Receptor Recognizes Both Self and Foreign MHC". In: Cell (2007)}}
  53. ## Allograft rejection is a major long-term problem
  54. ![Kidney allograft survival rates in children by transplant year[^kim-marks]](graphics/presentation/kidney-graft-survival.png){ height=65% }
  55. [^kim-marks]: [Kim & Marks. "Long-term outcomes of children after solid organ transplantation". In: Clinics (2014)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884158/?report=classic)
  56. ## Rejection is treated with immune suppressive drugs
  57. <!-- TODO: Need a graphic, or maybe a table of common drugs +
  58. mechanisms, or a diagram for periodic checking. -->
  59. ::: incremental
  60. * Graft recipient must take immune suppressive drugs indefinitely
  61. * Graft is monitored for rejection and dosage adjusted over time
  62. * Immune suppression is a delicate balance: too much and too little
  63. are both problematic.
  64. :::
  65. ## My thesis topics
  66. <!-- Needs revision -->
  67. ### Topic 1: Immune memory
  68. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  69. and memory $\mathsf{CD4}^{+}$ T-cell activation
  70. ### Topic 2: Diagnostics for rejection
  71. Improving array-based diagnostics for transplant rejection by
  72. optimizing data preprocessing
  73. ### Topic 3: Blood profiling during treatment
  74. Globin-blocking for more effective blood RNA-seq analysis in primate
  75. animal model for experimental graft rejection treatment
  76. ## Today's focus
  77. ### \Large Topic 1: Immune memory
  78. \Large
  79. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  80. and memory $\mathsf{CD4}^{+}$ T-cell activation
  81. ## Memory cells: faster, stronger, and more independent
  82. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-A-SVG.png)
  83. ## Memory cells: faster, stronger, and more independent
  84. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-B-SVG.png)
  85. ## Memory cells: faster, stronger, and more independent
  86. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-C-SVG.png)
  87. ## Memory cells: faster, stronger, and more independent
  88. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-D-SVG.png)
  89. ## Memory cells are a problem for immune suppression
  90. <!-- Need graphics? Or maybe just mark this slide as speaker notes for the previous one -->
  91. \large
  92. Compared to naïve cells, memory cells:
  93. \normalsize
  94. * respond to a lower antigen concentration
  95. * respond more strongly at any given antigen concentration
  96. * require less co-stimulation
  97. * are somewhat independent of some types of co-stimulation required by
  98. naïve cells
  99. * evolve over time to respond even more strongly to their antigen
  100. ## Memory cells are a problem for immune suppression
  101. \large
  102. Result:
  103. \normalsize
  104. * Memory cells require progressively higher doses of immune suppresive
  105. drugs
  106. * Dosage cannot be increased indefinitely without compromising the
  107. immune system's ability to fight infection
  108. ## We need a better understanding of immune memory
  109. * Cell surface markers of naïve and memory $\mathsf{CD4}^{+}$ T-cells
  110. are fairly well-characterized
  111. * But internal mechanisms that allow memory cells to respond
  112. differently to the same stimulus (antigen presentation) are not
  113. well-understood
  114. . . .
  115. * A reasonable hypothesis is that some of these mechanisms are
  116. epigenetic: using histone marks or DNA methylation to regulate the
  117. expression of certain genes
  118. * We can test this hypothesis by measuring gene expression (using
  119. RNA-seq) and histone methylation (using ChIP-seq) in naïve and
  120. memory T-cells before and after activation
  121. ## Experimental design
  122. * Separately isolate naïve and memory $\mathsf{CD4}^{+}$ T-cells from
  123. 4 donors
  124. * Activate with CD3/CD28 beads
  125. * Take samples at 4 time points: Day 0 (pre-activation), Day 1 (early
  126. activation), Day 5 (peak activation), and Day 14 (post-activation)
  127. * Do RNA-seq + ChIP-seq for 3 histone marks (H3K4me2, H3K4me3, &
  128. H3K27me3) for each sample.
  129. Data generated by Sarah Lamere, published in GEO as
  130. [GSE73214](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73214)
  131. ## A few intermediate analysis steps are required
  132. ![Flowchart of workflow for data analysis](graphics/CD4-csaw/rulegraphs/rulegraph-all-RASTER100.png)
  133. ## Histone modifications occur on consecutive histones
  134. ![ChIP-seq coverage in IL2 gene[^lamerethesis]](graphics/presentation/LaMere-thesis-fig3.9-SVG-CROP.png){ height=65% }
  135. [^lamerethesis]: Sarah LaMere. "Dynamic epigenetic regulation of CD4 T cell activation and memory formation". PhD thesis. TSRI, 2015.
  136. ## Histone modifications occur on consecutive histones
  137. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-A-SVG.png)
  138. ## Histone modifications occur on consecutive histones
  139. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-B-SVG.png)
  140. ## Histone modifications occur on consecutive histones
  141. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-C-SVG.png)
  142. ## SICER identifies enriched regions across the genome
  143. ![Finding "islands" of coverage with SICER[^sicer]](graphics/presentation/SICER-fig1-SVG.png)
  144. [^sicer]: [Zang et al. “A clustering approach for identification of enriched domains from histone modification ChIP-Seq data”. In: Bioinformatics 25.15 (2009)](https://doi.org/10.1093/bioinformatics/btp340)
  145. ## IDR identifies *reproducible* enriched regions
  146. ![Example irreproducible discovery rate[^idr] score consistency plot](graphics/presentation/IDR-example-CROP-RASTER.png){ height=65% }
  147. [^idr]: [Li et al. “Measuring reproducibility of high-throughput experiments”. In: AOAS (2011)](https://doi.org/10.1214/11-AOAS466)
  148. ## Finding enriched regions across the genome
  149. ![Peak-calling summary statistics](graphics/presentation/RCT-thesis-table2.2-SVG-CROP.png)
  150. ## Each histone mark has an "effective promoter radius"
  151. ![Enrichment of peaks near promoters](graphics/CD4-csaw/Promoter-Peak-Distance-Profile-PAGE1-CROP.pdf)
  152. ## Peaks in promoters correlate with gene expression
  153. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-A-SVG.png)
  154. ## Peaks in promoters correlate with gene expression
  155. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-B-SVG.png)
  156. ## Peaks in promoters correlate with gene expression
  157. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-C-SVG.png)
  158. ## Peaks in promoters correlate with gene expression
  159. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-D-SVG.png)
  160. ## Peaks in promoters correlate with gene expression
  161. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-Z-SVG.png)
  162. ## The story so far
  163. <!-- TODO: Left column: text; right column: flip through relevant image -->
  164. * H3K4me2, H3K4me3, and H3K27me3 occur on many consecutive histones in
  165. broad regions across the genome
  166. * These enriched regions occur more commonly within a certain radius
  167. of gene promoters
  168. * This "effective promoter radius" is consistent across all samples
  169. for a given histone mark, but differs between histone marks
  170. * Presence or absence of a peak within this radius is correlated with
  171. gene expression
  172. . . .
  173. Next: Does the position of a histone modification within a gene
  174. promoter matter to that gene's expression, or is it merely the
  175. presence or absence anywhere within the promoter?
  176. ## H3K4me2 promoter neighborhood K-means clusters
  177. ![Cluster means for H3K4me2](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  178. ## H3K4me2 promoter neighborhood cluster PCA
  179. :::::::::: {.columns}
  180. ::: {.column width="50%"}
  181. ![Cluster means for H3K4me2](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  182. :::
  183. ::: {.column width="50%"}
  184. ![PCA plot of promoters](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-PCA-CROP.png)
  185. :::
  186. ::::::::::
  187. ## H3K4me2 promoter neighborhood cluster expression
  188. :::::::::: {.columns}
  189. ::: {.column width="50%"}
  190. ![Cluster means for H3K4me2](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  191. :::
  192. ::: {.column width="50%"}
  193. ![Cluster expression distributions](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-expression-CROP-ROT90.png)
  194. :::
  195. ::::::::::
  196. ## H3K4me3 promoter neighborhood cluster PCA
  197. :::::::::: {.columns}
  198. ::: {.column width="50%"}
  199. ![Cluster means for H3K4me3](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-clusters-CROP.png)
  200. :::
  201. ::: {.column width="50%"}
  202. ![PCA plot of promoters](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-PCA-CROP.png)
  203. :::
  204. ::::::::::
  205. ## H3K4me3 promoter neighborhood cluster expression
  206. :::::::::: {.columns}
  207. ::: {.column width="50%"}
  208. ![Cluster means for H3K4me3](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-clusters-CROP.png)
  209. :::
  210. ::: {.column width="50%"}
  211. ![Cluster expression distributions](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-expression-CROP-ROT90.png)
  212. :::
  213. ::::::::::
  214. ## H3K27me3 promoter neighborhood cluster PCA
  215. :::::::::: {.columns}
  216. ::: {.column width="50%"}
  217. ![Cluster means for H3K27me3](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-clusters-CROP.png)
  218. :::
  219. ::: {.column width="50%"}
  220. ![PCA plot of promoters](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-PCA-CROP.png)
  221. :::
  222. ::::::::::
  223. ## H3K27me3 promoter neighborhood cluster expression
  224. :::::::::: {.columns}
  225. ::: {.column width="50%"}
  226. ![Cluster means for H3K27me3](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-clusters-CROP.png)
  227. :::
  228. ::: {.column width="50%"}
  229. ![Cluster expression distributions](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-expression-CROP-ROT90.png)
  230. :::
  231. ::::::::::
  232. ## What have we learned?
  233. ### H3K4me2 & H3K4me3
  234. * Peak closer to promoter $\Rightarrow$ more likely gene is highly
  235. expressed
  236. * Slightly asymmetric in favor of peaks downstream of TSS
  237. . . .
  238. ### H3K27me3
  239. * Depletion of H3K27me3 at TSS associated with elevated gene
  240. expression
  241. * Enrichment of H3K27me3 upstream of TSS even more strongly associated
  242. with elevated expression
  243. * Other coverage profiles not associated with elevated expression
  244. ## Differential modification disappears by Day 14
  245. ![Differential modification between naïve and memory samples at each time point](graphics/presentation/RCT-thesis-table2.4-A-SVG-CROP.png)
  246. ## Differential modification disappears by Day 14
  247. ![Differential modification between naïve and memory samples at each time point](graphics/presentation/RCT-thesis-table2.4-B-SVG-CROP.png)
  248. ## Convergence at Day 14 H3K4me2
  249. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-promoter-PCA-group-CROP.png)
  250. ## Convergence at Day 14 H3K4me3
  251. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-promoter-PCA-group-CROP.png)
  252. ## Convergence at Day 14 H3K27me3
  253. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-promoter-PCA-group-CROP.png)
  254. ## Convergence at Day 14 RNA-seq (PC 2 & 3)
  255. ![(Insert figure legend)](graphics/CD4-csaw/RNA-seq/PCA-final-23-CROP.png)
  256. ## MOFA identifies shared variation across all 4 data sets
  257. ![(Insert figure legend)](graphics/presentation/MOFA-varExplained-matrix-A-CROP.png)
  258. ## MOFA identifies shared variation across all 4 data sets
  259. ![(Insert figure legend)](graphics/presentation/MOFA-varExplained-matrix-B-CROP.png)
  260. ## MOFA shared variation captures convergence pattern
  261. ![(Insert figure legend)](graphics/CD4-csaw/MOFA-LF-scatter-small.png)
  262. ## What have we learned?
  263. * Almost no differential modification observed between naïve and
  264. memory at Day 14, despite plenty of differential modification at
  265. earlier time points.
  266. * RNA-seq data and all 3 histone marks' ChIP-seq data all show
  267. "convergence" between naïve and memory by Day 14 in the first 2 or 3
  268. principal coordinates.
  269. * MOFA captures this convergence pattern in one of the latent factors,
  270. indicating that this is a shared pattern across all 4 data sets.
  271. <!-- ## Slide -->
  272. <!-- ![(Insert figure legend)](graphics/CD4-csaw/LaMere2016_fig8.pdf) -->
  273. ## Takeaway 1: Each histone mark has an "effective promoter radius"
  274. * H3K4me2, H3K4me3, and H3K27me3 ChIP-seq reads are enriched in broad
  275. regions across the genome, representing areas where the histone
  276. modification is present
  277. * These enriched regions occur more commonly within a certain radius
  278. of gene promoters
  279. * This "effective promoter radius" is specific to each histone mark
  280. * Presence or absence of a peak within this radius is correlated with
  281. gene expression
  282. ## Takeaway 2: Peak position within the promoter is important
  283. * H3K4me2 and H3K4me3 peaks are more strongly associated with elevated
  284. gene expression the closer they are to the TSS, with a slight bias
  285. toward downstream peaks.
  286. * H3K27me3 depletion at the TSS and enrichement upstream are both
  287. associated with elevated expression, while other patterns are not.
  288. * In all histone marks, position of modification within promoter
  289. appears to be an important factor in association with gene
  290. expression
  291. ## Takeaway 3: Expression & epigenetic state both converge at Day 14
  292. * At Day 14, almost no differential modification observed between
  293. naïve and memory cells
  294. * Naïve and memory converge visually in PCoA plots
  295. * Convergence is a shared pattern of variation across all 3 histone
  296. marks and gene expression
  297. * This is consistent with the hypothesis that the naïve cells have
  298. differentiated into a more memory-like phenotype by day 14.